For the first time, an antisense oligonucleotide has been shown to be effective in treating relapse-remitting multiple sclerosis. A phase 2a clinical trial of Antisense Therapeutics Limited’s ATL1102, a CD49d antisense drug, showed that the treatment quickly reduced brain lesions in RRMS patients following the start of therapy. As a result, if trials continue and ATL1102 is brought to market, a new, highly effective treatment will be available that lacks the limitations of some current treatments.
“There are a number of unresolved issues with current multiple sclerosis drugs including the occurrence of neutralising antibodies to the antibody, protein, and peptide multiple sclerosis drugs as well as long-time safety concerns with the more recently approved drugs,” said Volker Limmroth, MD, PhD, of the University of Cologne, who was lead author of the study published in Neurology, in a news release. “There is a clear need for more effective and safe drugs for the significant population of multiple sclerosis patients who have relapses and non-stable disease.”
Dr. Limmroth, along with colleagues, published the results of the phase 2a trial under the title, “CD49d Antisense Drug ATL1102 Reduces Disease Activity in Patients with Relapse-Remitting MS.” A total of 77 patients were enrolled in the study, and all had relapsing-remitting multiple sclerosis. After only two months of dosing, ATL1102-treated patients showed a significantly lower cumulative number of new active brain lesions compared to placebo-treated patients.
Interestingly, the therapy was deemed to be as good as, or superior to, the popular multiple sclerosis drug Tysabri. Antisense Therapeutics estimates that ATL1102 could be a potentially safer, cheaper, and more convenient alternative to Tysabri therapy.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?